Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isoniazid Dose Adjustment by NAT2 Genotype in TB
NCT00571753Phase 3Terminated
- Sponsor
- University of Cologne
- Start
- Jun 2008
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of isoniazid in pulmonary tuberculosis (TB) (2 arms), sponsored by University of Cologne. Primary endpoint: Incidence of early treatment failure at 8 weeks. Started Jun 2008; status: terminated.
02
Drugs
isoniazid
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT00571753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00571753.